Ubs Group Ag Vera Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 82,374 shares of VERA stock, worth $3.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,374

Previous 74,462 10.63%

Holding current value

$3.48 Million

Previous $2.69 Million 35.12%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$34.09 - $46.71 $269,720 - $369,569	7,912 Added 10.63%	82,374 $3.64 Million
Q2 2024 Aug 13, 2024	SELL	$33.72 - $48.82 $1.75 Million - $2.53 Million	-51,921 Reduced 41.08%	74,462 $2.69 Million
Q1 2024 May 13, 2024	BUY	$14.91 - $49.14 $163,428 - $538,623	10,961 Added 9.5%	126,383 $5.45 Million
Q4 2023 Feb 09, 2024	BUY	$9.29 - $16.0 $664,114 - $1.14 Million	71,487 Added 162.71%	115,422 $1.78 Million
Q3 2023 Nov 09, 2023	BUY	$13.71 - $19.64 $318,099 - $455,687	23,202 Added 111.91%	43,935 $602,000
Q2 2023 Aug 11, 2023	BUY	$6.11 - $17.83 $72,098 - $210,393	11,800 Added 132.09%	20,733 $332,000
Q1 2023 May 12, 2023	BUY	$5.41 - $18.3 $43,474 - $147,058	8,036 Added 895.88%	8,933 $69,000
Q4 2022 Feb 08, 2023	SELL	$15.74 - $22.19 $69,271 - $97,658	-4,401 Reduced 83.07%	897 $17,000
Q3 2022 Nov 10, 2022	BUY	$13.27 - $22.31 $65,062 - $109,385	4,903 Added 1241.27%	5,298 $113,000
Q2 2022 Aug 10, 2022	SELL	$12.82 - $23.4 $20,691 - $37,767	-1,614 Reduced 80.34%	395 $5,000
Q1 2022 May 16, 2022	BUY	$17.8 - $28.06 $35,760 - $56,372	2,009 New	2,009 $47,000
Q3 2021 Nov 15, 2021	SELL	$13.71 - $30.6 $13,106 - $29,253	-956 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$11.5 - $19.97 $10,994 - $19,091	956 New	956 $13,000

Others Institutions Holding VERA

# of Institutions

184

Shares Held

55.2M

Call Options Held

134K

Put Options Held

156K

View Full List

About Vera Therapeutics, Inc.

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.14B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

More about VERA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account